Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Mar 1;4(3):e213520.
doi: 10.1001/jamanetworkopen.2021.3520.

Association of Obesity With Survival Outcomes in Patients With Cancer: A Systematic Review and Meta-analysis

Fausto Petrelli  1 , Alessio Cortellini  2 , Alice Indini  3 , Gianluca Tomasello  3 , Michele Ghidini  3 , Olga Nigro  4 , Massimiliano Salati  5 , Lorenzo Dottorini  6 , Alessandro Iaculli  6 , Antonio Varricchio  7 , Valentina Rampulla  7 , Sandro Barni  1 , Mary Cabiddu  1 , Antonio Bossi  8 , Antonio Ghidini  9 , Alberto Zaniboni  10
Affiliations
Meta-Analysis

Association of Obesity With Survival Outcomes in Patients With Cancer: A Systematic Review and Meta-analysis

Fausto Petrelli et al. JAMA Netw Open. .

Abstract

Importance: Obesity, defined as a body mass index (BMI) greater than 30, is associated with a significant increase in the risk of many cancers and in overall mortality. However, various studies have suggested that patients with cancer and no obesity (ie, BMI 20-25) have worse outcomes than patients with obesity.

Objective: To assess the association between obesity and outcomes after a diagnosis of cancer.

Data sources: PubMed, the Cochrane Library, and EMBASE were searched from inception to January 2020.

Study selection: Studies reporting prognosis of patients with obesity using standard BMI categories and cancer were included. Studies that used nonstandard BMI categories, that were limited to children, or that were limited to patients with hematological malignant neoplasms were excluded. Screening was performed independently by multiple reviewers. Among 1892 retrieved studies, 203 (17%) met inclusion criteria for initial evaluation.

Data extraction and synthesis: The Meta-analysis of Observational Studies in Epidemiology (MOOSE) and Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines were reporting guideline was followed. Data were extracted by multiple independent reviewers. Risk of death, cancer-specific mortality, and recurrence were pooled to provide an adjusted hazard ratio (HR) with a 95% CI . A random-effects model was used for the retrospective nature of studies.

Main outcomes and measures: The primary outcome of the study was overall survival (OS) in patients with cancer, with and without obesity. Secondary end points were cancer-specific survival (CSS) and progression-free survival (PFS) or disease-free survival (DFS). The risk of events was reported as HRs with 95% CIs, with an HR greater than 1 associated with a worse outcome among patients with obesity vs those without.

Results: A total of 203 studies with 6 320 365 participants evaluated the association of OS, CSS, and/or PFS or DFS with obesity in patients with cancer. Overall, obesity was associated with a reduced OS (HR, 1.14; 95% CI, 1.09-1.19; P < .001) and CSS (HR, 1.17; 95% CI, 1.12-1.23; P < .001). Patients were also at increased risk of recurrence (HR, 1.13; 95% CI, 1.07-1.19; P < .001). Conversely, patients with obesity and lung cancer, renal cell carcinoma, or melanoma had better survival outcomes compared with patients without obesity and the same cancer (lung: HR, 0.86; 95% CI, 0.76-0.98; P = .02; renal cell: HR, 0.74; 95% CI, 0.53-0.89; P = .02; melanoma: HR, 0.74; 95% CI, 0.57-0.96; P < .001).

Conclusions and relevance: In this study, obesity was associated with greater mortality overall in patients with cancer. However, patients with obesity and lung cancer, renal cell carcinoma, and melanoma had a lower risk of death than patients with the same cancers without obesity. Weight-reducing strategies may represent effective measures for reducing mortality in these patients.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Cortellini reported receiving grants from AstraZeneca, Roche, Merck Sharpe and Dohme, Bristol Myers Squibb, Astellas, and Novartis outside the submitted work. Dr Bossi reported receiving grants from Lilly Italia, Novo Nordisk, Bayer, Merck Sharpe and Dohme Italia, Sanofi, and Pikdare outside the submitted work. No other disclosures were reported.

Figures

Figure.
Figure.. Flow Diagram of Included Studies
See this image and copyright information in PMC

References

    1. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. World Health Organization; 2000. Accessed February 24, 2021. https://www.who.int/nutrition/publications/obesity/WHO_TRS_894/en/ - PubMed
    1. Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019;92:6-10. doi: 10.1016/j.metabol.2018.09.005 - DOI - PubMed
    1. Aune D, Sen A, Prasad M, et al. BMI and all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants. BMJ. 2016;353:i2156. doi: 10.1136/bmj.i2156 - DOI - PMC - PubMed
    1. Lavie CJ, Sharma A, Alpert MA, et al. Update on obesity and obesity paradox in heart failure. Prog Cardiovasc Dis. 2016;58(4):393-400. doi: 10.1016/j.pcad.2015.12.003 - DOI - PubMed
    1. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9:88. doi: 10.1186/1471-2458-9-88 - DOI - PMC - PubMed